Zai Lab Ltd stock (US98887Q1040): Nasdaq-listed biotech trades lower after Q1 2026 update and ahead of next earnings
02.06.2026 - 09:12:30 | ad-hoc-news.de
Zai Lab Ltd shares on the Nasdaq Global Select Market in the United States continue to trade well below the levels implied by recent analyst models after the China-focused biotech reported its Q1 2026 figures on 05/07/2026 and as the market starts to position for the next estimated quarterly earnings release in early August, according to MarketBeat as of 05/29/2026.
According to MarketBeat, the stock closed at USD 17.69 on 05/29/2026 on Nasdaq, with a marginal move in extended trading to USD 17.66 the same day, putting the company at a significant discount to the average 12-month price target compiled from eight Wall Street analysts as of 05/29/2026.
In Germany, the Zai Lab Ltd stock is also available to investors via off-exchange platforms such as Tradegate under the ticker ZLAB, giving euro-based investors an additional way to react to developments in the United States and China around the company and its late-stage oncology pipeline, according to German trading venue data as of 05/31/2026.
Zai Lab Ltd reported its Q1 2026 earnings on 05/07/2026, posting a loss per share of USD -0.46 compared with a MarketBeat consensus forecast of USD -0.53, meaning the company came in USD 0.07 ahead of that analyst estimate in the quarter, based on MarketBeat data as of 05/07/2026.
On the top line, the company generated revenue of USD 99.61 million in Q1 2026 according to the same MarketBeat earnings overview, which aggregates figures from the companys quarterly filing and press release published on 05/07/2026.
The stock market is also starting to look ahead to the next set of numbers, with MarketBeat indicating that Zai Labs next earnings date is currently estimated for 08/06/2026 based on its historical reporting schedule, although the company has not yet formally confirmed that date as of the end of May 2026.
For investors following regulatory disclosures in the companys home market, the Q1 2026 earnings release and related Form 10-Q were filed with the US Securities and Exchange Commission on 05/07/2026, providing detailed segment information and updates on the progress of key oncology and autoimmune assets that underpin the companys collaboration-heavy business model.
As of: 06/02/2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: ZLAB
- Sector/industry: Biopharmaceuticals / oncology-focused drug development
- Headquarters/country: Shanghai, China
- Core markets: China and other Asia-Pacific markets, with selected products and partnerships targeting the United States and global markets
- Key revenue drivers: Commercial oncology and autoimmune therapies in China, milestone and collaboration payments from global pharma partners, and potential royalties from licensed products
- Home exchange/listing venue: Nasdaq Global Select Market (ZLAB)
- Trading currency: USD
Zai Lab Ltd: core business model
Operating as an oncology and immunology specialist, Zai Lab Ltd concentrates on bringing innovative therapies to market in China and broader Asia by in-licensing or co-developing late-stage assets from global pharmaceutical partners and then generating revenue mainly from product sales, milestones, and future royalty streams once those drugs are commercialized.
Latest quarterly results for Zai Lab Ltd at a glance
The most recent quarterly data point for Zai Lab Ltd is the Q1 2026 update released on 05/07/2026, where the company reported earnings per share of USD -0.46 versus a MarketBeat consensus expectation of USD -0.53, implying that the bottom-line loss per share was modestly narrower than analysts had modeled for the period.
MarketBeat also reports that revenue in the same quarter came in at USD 99.61 million on 05/07/2026, reflecting the performance of Zai Labs marketed portfolio and collaboration income and serving as the latest benchmark for investors evaluating whether the company can sustain or accelerate its top-line trajectory in upcoming quarters.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Zai Lab Ltd
The market reaction to Zai Lab Ltds Q1 2026 figures and the gap between the current share price and published analyst targets has prompted active discussion among traders and biotech-focused investors across social platforms.
Conclusion
Zai Lab Ltd remains an actively traded Nasdaq biotech name from China, with the most recent visibility coming from its Q1 2026 earnings release on 05/07/2026 that showed a narrower loss per share and revenue of USD 99.61 million compared with consensus expectations, according to MarketBeat.
With the share price around USD 17.69 on 05/29/2026 and the next earnings date currently estimated for 08/06/2026, the stock will likely continue to be influenced by data updates on its oncology and autoimmune pipeline, as well as any changes in analyst assumptions embedded in the current set of published models.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
So schätzen die Börsenprofis ZLAB Aktien ein!
Für. Immer. Kostenlos.
